文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

多巴胺与去甲肾上腺素治疗休克比较的不同统计学方法探索:SOAP II

Exploration of different statistical approaches in the comparison of dopamine and norepinephrine in the treatment of shock: SOAP II.
PubMed 文献 · Crit Care · 2024-09-10
一句话结论SOAP II再分析显示,感染性和心源性休克患者使用多巴胺均与伤害相关,未发现多巴胺优于去甲肾上腺素的亚组。

本研究对SOAP II试验中1679例休克患者进行再分析,采用win-ratio(WR)、贝叶斯再分析及基于风险和基于效应的治疗效应异质性(HTE)探索,评估多巴胺与去甲肾上腺素的比较。所有分析均倾向于去甲肾上腺素优于多巴胺:WR 0.79(95%CI 0.68-0.92;p=0.003),贝叶斯再分析显示多巴胺对死亡、复合终点和DAFICU28的伤害概率分别为0.95、>0.99和0.91。基于效应的HTE模型未推荐多巴胺优于去甲肾上腺素用于任何可能修饰因素组合;当模型推荐去甲肾上腺素而实际使用多巴胺时,复合终点绝对增加6%。结论提示多巴胺在感染性和心源性休克中均与伤害相关,未发现有利亚组。

要点

  • 在1679例休克患者(62%感染性、17%心源性)中,WR分析显示多巴胺赢率少于去甲肾上腺素(WR 0.79;95%CI 0.68-0.92;p=0.003)。
  • 贝叶斯再分析显示多巴胺的伤害概率:死亡0.95、复合终点>0.99、DAFICU28 0.91;心源性休克中DAFICU28减少更明显(0.92)。
  • 基于效应的HTE模型未推荐多巴胺优于去甲肾上腺素用于任何年龄、休克类型、心肌病或SOFA评分的组合。
  • 当基于效应的模型推荐去甲肾上腺素而实际使用多巴胺时,复合终点绝对增加6%。
  • 基于风险的HTE显示,在预测死亡风险最高四分位组中,多巴胺很可能减少DAFICU28。

适用人群与场景

  • SOAP II试验纳入的所有休克患者,平均年龄64.9岁,57%男性,62%感染性休克,17%心源性休克。

研究设计与关键结果

  • 再分析纳入1679例患者(平均年龄64.9岁,57%男性,62%感染性休克,17%心源性休克)。
  • WR分析显示多巴胺赢率少于去甲肾上腺素(WR 0.79;95%CI 0.68-0.92;p=0.003),在感染性和心源性休克亚组中均明显。
  • 贝叶斯再分析显示多巴胺的伤害概率:死亡0.95、复合终点>0.99、DAFICU28 0.91;心源性休克中DAFICU28减少更明显(0.92)。
  • 基于风险的HTE显示,在预测死亡风险最高四分位组中,多巴胺很可能减少DAFICU28。
  • 基于效应的HTE模型未推荐多巴胺优于去甲肾上腺素用于任何年龄、休克类型、心肌病或SOFA评分的组合;当模型推荐去甲肾上腺素而实际使用多巴胺时,复合终点绝对增加6%。

证据类型、等级与局限

  • 研究类型:对SOAP II试验的再分析;证据等级:原文未给出。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 再分析结果提示,对感染性和心源性休克患者,多巴胺与去甲肾上腺素相比未显示优势,且与伤害相关。
  • 基于效应的HTE模型未推荐多巴胺优于去甲肾上腺素用于任何评估的修饰因素组合。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Exploring clinical trial data using alternative methods may enhance original study's findings and provide new insights. The SOAP II trial has been published more than 10 years ago; but there is still some speculation that some patients may benefit from dopamine administration for shock management. We aimed to reanalyse the trial under different approaches and evaluate for heterogeneity in treatment effect (HTE).

METHODS: All patients enrolled in SOAP II were eligible for reanalysis. We used a variety of methods including the win-ratio (WR), a Bayesian reanalysis stratified according to shock type, and both a risk-based and effect-based explorations for HTE. The methods were applied to different endpoints, including a hierarchy of death, new use of renal-replacement therapy (RRT), and new-onset arrhythmia; 28-day mortality; a composite endpoint (mortality, new use of RRT, and new-onset arrhythmia), and days alive and free of ICU at 28-days (DAFICU28).

RESULTS: A total of 1679 patients were included (average age was 64.9 years, 57% male, 62% with septic and 17% with cardiogenic shock). All analysis favoured norepinephrine over dopamine. Under the WR approach, dopamine had fewer wins compared to norepinephrine (WR 0.79; 95% confidence intervals [CI] 0.68-0.92; p = 0.003), evident in both cardiogenic and septic shock subgroups. The Bayesian reanalysis for type of shock showed, for dopamine, a probability of harm of 0.95 for mortality, > 0.99 probability of harm for composite endpoint, and 0.91 probability of harm for DAFICU28. The fewer DAFICU28 with dopamine was more apparent in those with cardiogenic shock (0.92). Under the risk-based HTE, there was a high probability that dopamine resulted fewer DAFICU28 in the highest quartile of predicted mortality risk. The effect-based HTE assessment model did not recommended dopamine over norepinephrine for any combination of possible modifiers including age, type of shock, presence of cardiomyopathy, and SOFA score. Receiving dopamine when the effect-based model recommended norepinephrine was associated with an absolute increase in composite endpoint of 6%.

CONCLUSION: The harm associated with the use of dopamine for the management of shock appears to be present in both septic and cardiogenic shock patients. There was no suggestion of any subgroup in which dopamine was found to be favourable over norepinephrine.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Zampieri FG, Bagshaw SM, Njimi H, et al. Exploration of different statistical approaches in the comparison of dopamine and norepinephrine in the treatment of shock: SOAP II. Crit Care. 2024. PMID: 39256813. doi:10.1186/s13054-024-05016-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。